Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Kelch-like protein 2 (KLHL2) is a member of the Kelch-like protein family, acting as a substrate-specific adapter of a BTB-CUL3-RBX1 (BCR) E3 ubiquitin ligase complex. KLHL2 mediates the ubiquitination and subsequent proteasomal degradation of specific protein substrates, including WNK kinases (WNK1, WNK3, WNK4) and NPTXR. It is involved in reorganization of the actin cytoskeleton and promotes the growth of cell projections in oligodendrocyte precursor cells. It is primarily a cytoskeletal and regulatory protein, not a classical receptor or enzyme target, but is increasingly recognized as relevant for cell biology and disease. Its main known disease association is with pseudohypoaldosteronism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Kelch-like protein 2 (KLHL2).